Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric, International, Randomized, Double-Blind, Placebo-Controlled, Phase II/III (MYODA-INT) Study to Evaluate the Safety and Efficacy of a Sarconeos Dose in Ambulant Boys with Duchenne Myopathy

Trial Profile

A Multicentric, International, Randomized, Double-Blind, Placebo-Controlled, Phase II/III (MYODA-INT) Study to Evaluate the Safety and Efficacy of a Sarconeos Dose in Ambulant Boys with Duchenne Myopathy

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 31 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms MYODA-INT
  • Sponsors Biophytis
  • Most Recent Events

    • 31 Oct 2019 According to an Biophytis media release, the company expects to file IND with FDA in Q4 2019.
    • 02 Oct 2019 According to an Biophytis media release, this trial is expected to commence in 2020.
    • 02 Oct 2019 According to an Biophytis media release, two posters highlighting the innovative MYODA clinical trial design will be presented at the 24th International Annual Congress of the World Muscle Society (WMS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top